DEM BioPharma Funding & Investors
DEM Bio is pioneering the next generation of immunotherapeutics that unleash macrophages and immune phagocytes to eliminate tumors by targeting ‘Don’t eat me’ (DEM) and ‘Eat me’ (EM) signals on cancer cells and macrophages. Founded by Longwood Fund and is supported by a syndicate of biotech investors and headquartered in Boston, MA.
dembiopharma.comTotal Amount Raised: $70,000,000
DEM BioPharma Funding Rounds
Series A
$70,000,000
Series A Investors
Alta PartnersLongwood FundInsight Venture PartnersAlexandria Venture InvestmentsAstellas Venture ManagementPfizer Venture InvestmentsUTokyo Innovation Platform Co.Emerson Collective
Funding info provided by Diffbot.